Engineering a single-chain antibody against Trypanosoma cruzi metacyclic trypomastigotes to block cell invasion

PLoS One. 2019 Oct 16;14(10):e0223773. doi: 10.1371/journal.pone.0223773. eCollection 2019.

Abstract

Trypanosoma cruzi is a flagellate protozoan pathogen that causes Chagas disease. Currently there is no preventive treatment and the efficiency of the two drugs available is limited to the acute phase. Therefore, there is an unmet need for innovative tools to block transmission in endemic areas. In this study, we engineered a novel recombinant molecule able to adhere to the T. cruzi surface, termed scFv-10D8, that consists of a single-chain variable fragment (scFv) derived from mAb-10D8 that targets gp35/50. The synthetic gene encoding scFv-10D8 was cloned and fused to a 6×His tag and expressed in a prokaryotic expression system. Total periplasmic or 6xHis tag affinity-purified fractions of scFv-10D8 retained the capacity to bind to gp35/50, as shown by Western blot analyses. Pre-incubation of metacyclic trypomastigotes with scFv-10D8 showed a remarkable reduction in cell invasion capacity. Our results suggest that scFv-10D8 can be used in a paratransgenic approach to target parasites in insect vectors, avoiding dissemination of infective forms. Such advances in the development of this functional molecule will surely prompt the improvement of alternative strategies to control Chagas disease by targeting mammalian host stages.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Protozoan / genetics
  • Antibodies, Protozoan / pharmacology
  • Antigens, Protozoan / immunology*
  • Cell Line
  • Chagas Disease / drug therapy
  • Chagas Disease / parasitology
  • Chagas Disease / prevention & control
  • HeLa Cells
  • Humans
  • Protein Engineering / methods*
  • Recombinant Proteins / genetics
  • Recombinant Proteins / pharmacology
  • Single-Chain Antibodies / genetics*
  • Single-Chain Antibodies / pharmacology
  • Trypanosoma cruzi / drug effects
  • Trypanosoma cruzi / immunology*

Substances

  • Antibodies, Protozoan
  • Antigens, Protozoan
  • Recombinant Proteins
  • Single-Chain Antibodies

Grants and funding

WDR was supported by Grant #48.018, Fundação Araucária (PPSUS -SESA/PR, MS-Decit), http://www.fappr.pr.gov.br/; Grant number 311376/2017-7, National Counsel of Technological and Scientific Development (CNPq), http://www.cnpq.br. JFM was supported by Grant number PVE 401355/2014-4 and DT 303733/2016-0, National Counsel of Technological and Scientific Development (CNPq), http://www.cnpq.br. The authors are supported by the Fundação Araucária (PPSUS -SESA/PR, MS-Decit), National Counsel of Technological and Scientific Development (CNPq), and CAPES agency (FINEP, PROEX PROAP programs). LMKD, PB, JFM, NY, and WDD, RAMA and JFM have scholarships from CNPq, and RJS, JSM, and LAPL have scholarships from CAPES. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.